Clinical effectiveness of CT-P13 (infliximab biosimilar) used as a switch fromremicade (infliximab) in patients with established rheumatic disease. report of clinical experience based on prospective observational data

Expert Opinion on Biological Therapy

Volumn 15, Issue 12, 2015, Pages 1677-1683

  Nikiphorou, Elena ^a   Kautiainen, Hannu ^b   Hannonen, Pekka ^a   Asikainen, Juha ^a   Kokko, Arto ^a   Rannio, Tuomas ^a   Sokka, Tuulikki ^a,c  

^a JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^b Medcare Foundation   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Ankylosing spondylitis; Biosimilars infliximab; Rheumatoid arthritis

Indexed keywords

AZATHIOPRINE; BIOLOGICAL MARKER; BIOSIMILAR AGENT; C REACTIVE PROTEIN; DRUG ANTIBODY; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; RITUXIMAB; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT; CT-P13; MONOCLONAL ANTIBODY;

ADULT; AGED; ANKYLOSING SPONDYLITIS; AREA UNDER THE CURVE; ARTICLE; CHRONIC ARTHRITIS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LATENT TUBERCULOSIS; LUNG TUBERCULOSIS; MALE; MIDDLE AGED; MONOTHERAPY; NEUROFIBROMATOSIS; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; PSORIATIC ARTHRITIS; REACTIVE ARTHRITIS; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT DURATION; YOUNG ADULT; FOLLOW UP; PROCEDURES; RHEUMATIC DISEASES; SELF REPORT; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BIOSIMILAR PHARMACEUTICALS; DRUG SUBSTITUTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLIXIMAB; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RHEUMATIC DISEASES; SELF REPORT; TREATMENT OUTCOME;

EID: 84946601256     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2015.1103733     Document Type: Article

References (20)

1. Sokka T, Kautiainen H, Pincus T, et al. Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. Ann Rheum Dis. 2009;68(11):1666-1672. Indicates unmet need for inexpensive antirheumatic medications in many countries.
2. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354(9194):1932-1939.
3. Brodszky V, Baji P, Balogh O, et al. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. Eur J Health Econ. 2014;15(Suppl 1):S65-71. Real-world estimation of benefits of biosimilars due to lower price
4. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613-1620. An original RCT of the biosimilar
5. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallelgroup, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605-1612. An original RCT of the biosimilar
6. Biosimilar monoclonal antibody approved in Korea/News/Biosimilars/Home - GaBI online - Generics and Biosimilars Initiative. [cited 2015 Mar. 9]. Available from: http://www.gabionline.net/Biosimilars/News/Biosimilar-monoclonalantibodyapproved-in-Korea.
7. Espinosa Morales R, Díaz Borjón A, Barile Fabris LA, et al. Biosimilar drugs in Mexico: position of the Mexican College of Rheumatology, 2012. Reumatol Clin. 2013;9(2):113-116.
8. Fonseca JE, Gonçalves J, Araújo F, et al. The Portuguese Society of Rheumatology position paper on the use of biosimilars. Acta Reumatol Port. 2014;39(1):60-71.
9. Atzeni F, Sebastiani M, Ricci C, et al. Position paper of Italian rheumatologists on the use of biosimilar drugs. Clin Exp Rheumatol. 2015;33(1):1-4.
10. Position paper - Sweden [Internet]. 2015 [cited 2015 Mar. 31]. Available from: http://www.svenskreumatologi.se/sites/default/file.
11. Position paper - American College of Rheumatology [Internet]. 2015 [cited 2015 Mar. 31]. Available from: https://www.rheumatology.org/Practice/Clinical/Pos.
12. Position paper - BSR [Internet]. 2015 [cited 2015 Mar. 31]. Available from: http://www.rheumatology.org.uk/about-bsr/press-rel.
13. Sokka T, Haugeberg G, Pincus T. Assessment of quality of rheumatoid arthritis care requires joint count and/or patient questionnaire data not found in a usual medical record: examples from studies of premature mortality, changes in clinical status between 1985 and 2000, and a QUESTRA global perspective. Clin Exp Rheumatol. 2007;25(6 Suppl 47):86-97.
14. Baji P, Péntek M, Szántó S, et al. Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis. Eur J Health Econ. 2014;15(Suppl 1):S45-52.
15. Dörner T, Strand V, Castañeda-Hernández G, et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis. 2013;72(3):322-328.
16. Park W, Miranda P, Brzosko M, et al. Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with ankylosing spondylitis: comparison between continuing with CT-P13 and switching from infliximab to CT-P13. Arthritis Rheum. 2013;65(12):3326.
17. Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with rheumatoid arthritis: comparison between continued CT-P13 and switching from infliximab to CT-P13. Arthritis Rheum. 2013;65(12):3319.
18. Putrik P, Ramiro S, Kvien TK, et al. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?. Ann Rheum Dis. 2014;73(11):2010-2021.
19. Cornes P. The economic pressures for biosimilar drug use in cancer medicine. Target Oncol. 2012;7(Suppl 1):S57-67.
20. Position paper Finland [Internet]. 2015 [cited 2015 Aug. 31]. Available from: http://www.reumatologinenyhdistys.fi/files/sry-kannanotto-biosimilaarilaakkei siin-050615.pdf. Affiliation